This Options Trade Could Net A Quick 300% Gain By Taking Advantage Of Financials’ Weakness

Today’s article outlines an options trade that could net a quick 300% gain by taking advantage of one of the weakest sectors in the market today (even before COVID-19 hit): financials. This trade is premised on the belief that “If stocks stay firm for a while longer, it is very unlikely that lagging financials will suddenly start to lead. And if the market faces another big sell-off before finding its ultimate bottom – which we think is the case – chances are that the weakest stocks are going to get hurt the most.” For more, CLICK HERE.

Read More

The “Optimal” Pre-Midterm Financials Trade?

With many traders positioning themselves ahead of the midterm elections – and what the results may mean for congressional control and various policies – today’s article highlights one potential trade idea focused on one specific sector: financials. For the particulars of this trade idea – a covered call which the author sees as low-risk and “probably the optimal way to trade the scenario” – CLICK HERE.

Read More

This Company Is At The Top Of The Internet Of Things Supply Chain. Is It The Top IofT Stock?

2017-10-29 19_26_41-Silver Iphone 6 Plus and Macbook Air on Wooden Table · Free Stock PhotoWhich stock is the best pick for playing the hot Internet of Things theme? RBC Capital believes that it has the answer: a company that sits at the very top of the IofT supply chain. Specifically, this company “codes the software that operates the machines that make the chips that make the Internet of Things possible.” What is the company in question – and do its financials warrant its designation as the best IofT stock? CLICK HERE.

Read More

12 Emerging Pharmaceutical Companies – And The Multiple Catalysts 2017 Holds For Each Of Them

2017-02-12 19_23_47-Bunch of White Oval Medication Tablets and White Medication Capsules · Free StocToday’s article highlights a dozen emerging pharmaceutical companies that could potentially have a big year – and identifies the multiple catalysts that 2017 holds for each of them – from financials releases to key clinical trial milestones to potential acquisition. To find out what these 12 emerging pharmaceutical companies are, what the analyst sentiment on them is, and what their respective catalysts this year are (and when they are set to occur), CLICK HERE.

Read More

Are Investors Blindly Banking On Bank Stocks?

2016-11-20 19_46_15-Morguefile free photographs for commercial useGiven president-elect Trump’s promise to repeal the financial regulations ushered in under Dodd-Frank and the potential for his fiscal stimulus and tax-cut plans to bring an end to the era of low inflation, it is not surprising investors have been flocking to financials, making the sector one of the biggest beneficiaries of Trump’s victory. Why, then, does the author of today’s article argue that investors have “blindly taken [Trump’s win] as a reason to buy bank stocks” and caution against following the herd? What does he suggest as a better way to play financials? CLICK HERE to find out.

Read More

Taking Stock Of The Rest Of 2016

2016-08-29 07_08_46-Morguefile.com free stock photosThere are only four months left to go in 2016, but with markets hovering around record highs, uncertainty regarding the prospect of an interest rate hike by the Fed, the presidential election, the potential for as-yet unseen Brexit fallout on Europe and beyond, among a plethora of other concerns, the author of today’s article offers up several “portfolio management ideas for consideration for the balance of 2016.” For the author’s recommendations on managing everything from the U.S. bull market, European investments in light of Brexit, REITs as they become their own sector separate from financials, and much more, CLICK HERE.

Read More